Over 4,300 confirmed cases reported

The outbreak has resulted in 2,011 fatalities out of 4,381 confirmed cases, with a staggering mortality rate of 45.9%, as reported by national health authorities. Originating in Ituri Province in the northeast, the virus has now infiltrated multiple regions including North Kivu, where ongoing conflicts and severely weakened healthcare systems have exacerbated the crisis. This current outbreak now rivals the devastating 2018-2020 epidemic, which previously held the grim record with nearly 2,300 deaths.

Experimental vaccine trial underway for Bundibugyo variant

The current outbreak is driven by the Bundibugyo Ebola variant, for which no approved vaccine currently exists. The World Health Organization has authorized an emergency clinical trial of Ervebo—the only Ebola vaccine with existing approval—to evaluate its effectiveness against this strain. Given the extensive safety data already collected on Ervebo, health experts are proceeding directly to Phase 3 trials, typically conducted on a larger scale. The Gavi Vaccine Alliance has pledged to supply doses from the global Ervebo stockpile, which contains approximately 500,000 doses. The vaccine is manufactured by the American pharmaceutical company Merck.

Global collaboration accelerates vaccine development

In addition to Ervebo, multiple experimental vaccines are in various stages of development to combat the Bundibugyo variant. Health authorities in Canada have granted Moderna the green light to initiate clinical trials for their candidate. Meanwhile, research teams at Hilleman Laboratories and the University of Oxford are advancing their own vaccine candidates. In response to the escalating crisis, the United States has committed an additional $242 million in emergency funding to bolster Ebola containment efforts in DRC.